Below is a letter that Carol L. Alexander, OD, FAAO, Director, Professional Communications, at Johnson & Johnson Vision Care, released to eye care professionals and customers regarding the Contact Lens Consumers Health Protection Act.
Last year, the Federal Trade Commission (FTC) began its scheduled review of the Fairness to Contact Lens Consumers Act of 2004 (FCLCA). Many committed to vision health – the American Optometric Association (AOA), Johnson & Johnson Vision Care, Inc. (JJVCI), and the Coalition for Patient Vision Care Safety provided formal feedback during the open comment period concluding on October 25, 2015.
As Congress enters into its August recess and the current Administration begins its final months of work, the FTC is working hard to finalize its initial response to the more than 600 comments received in the review process before the close of this term.
And they’re not alone. On August 3, along with our partners in the Coalition for Patient Vision Care Safety, JJVCI participated in another meeting with the FTC, this time with FTC Commissioner Maureen Ohlhausen. During the conversation, we emphasized the FTC’s opportunity to safeguard vision health and safety and promote consumer choice through better understanding of the risk to consumers when contact lenses are purchased without professional oversight. We also reiterated our concerns around the existing passive verification process by highlighting real examples of how ongoing issues have affected patients’ health, illustrating the need to modernize the process.
Improving on existing protections continues beyond our meeting with the FTC when advocates across our industry lend their voice and perspective. Two of those valued voices include Dr. Timothy L. Hodges, M.D., and Dr. Jeffrey Sonsino, O.D., FAAO whose commentary, “Seeing 20/20 on the Contact Lens Consumers Health Protection Act,” was featured yesterday in The Hill, a Capitol Hill political and policy news outlet. In the piece, Drs. Hodges and Sonsino clarify the intent of the Contact Lens Consumers Health Protection Act (S. 2777) and share why the updates included in the bill are vital to patients’ health and safety.
We invite you to share the publication with your colleagues, patients, and fellow vision care advocates and for more information about how you can add your voice to our collective effort to strengthen patient safeguards, visit our website.
As always, on behalf of Johnson & Johnson Vision Care, we thank you for your commitment to promoting patient’s health and safety. Please continue to contact me at firstname.lastname@example.org with your perspectives, insights, and feedback.
Carol L. Alexander, O.D., F.A.A.O.
Director, Professional Communications